CJC-1295

A GHRH analog often paired with ipamorelin. Limited human data, and nonclinical findings have flagged safety concerns. Remains restricted under FDA compounding rules as of May 2026 — separate from the peptides removed from Category 2.

Anthivera’s calibrated five-tier scale — what the strongest evidence on CJC-1295 actually supports today.

1. PreclinicalCJC-1295
2. Limited clinical
3. Multiple human studies
4. Phase 3
5. FDA-approved

Preclinical: Animal / in vitro / mechanistic data only.

Dated milestones in CJC-1295’s U.S. regulatory path.

1. Late 2023

   Placed on FDA Category 2 (do-not-compound list), restricting compounding-pharmacy access.

2. April 23, 2026

   NOT removed from Category 2 with the April 2026 group — classified as a developmental drug with adverse nonclinical findings.

1. 01What evidence is there for CJC-1295 in women specifically — and does that include perimenopausal or postmenopausal cohorts?
2. 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
3. 03What baseline labs do you require before starting, and how often do you monitor?
4. 04What are the realistic timelines and what does “not working for you” look like in practice?

• Canopy Telehealth Clinic

  Broad catalog and broad geographic reach; longer intake process but thorough lab work.

  4.0/5

See the full provider comparison for all peptides side by side.